Nicholas J. Ashton

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

Thomas K. Karikari, Tharick A. Pascoal, Nicholas J. Ashton et al. · The Lancet Neurology · 2020 · 1.3K citations

Alzheimer's Disease, Dementia, Prospective Cohorts +11

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

Nicholas J. Ashton, Tharick A. Pascoal, Thomas K. Karikari et al. · Acta Neuropathologica · 2021 · 668 citations · Full text

Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

Nicholas J. Ashton, Wagner S. Brum, Guglielmo Di Molfetta et al. · JAMA Neurology · 2024 · 616 citations · Full text

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

Andréa Lessa Benedet, Marta Milà‐Alomà, Agathe Vrillon et al. · JAMA Neurology · 2021 · 566 citations · Full text

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

Joana B. Pereira, Shorena Janelidze, Ruben Smith et al. · Brain · 2021 · 532 citations · Full text